Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05177770
Title Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Recruitment Terminated
Gender male
Phase Phase II
Variant Requirements No
Sponsors Surface Oncology
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.